[go: up one dir, main page]

ES2159573T3 - Acetilhidrolasa del factor activador de plaquetas. - Google Patents

Acetilhidrolasa del factor activador de plaquetas.

Info

Publication number
ES2159573T3
ES2159573T3 ES94930623T ES94930623T ES2159573T3 ES 2159573 T3 ES2159573 T3 ES 2159573T3 ES 94930623 T ES94930623 T ES 94930623T ES 94930623 T ES94930623 T ES 94930623T ES 2159573 T3 ES2159573 T3 ES 2159573T3
Authority
ES
Spain
Prior art keywords
acetilhidrolasa
activator factor
activating factor
platelet
plate activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94930623T
Other languages
English (en)
Inventor
Laurence S Cousens
Christine D Eberhardt
Patrick Gray
Trong Hai Le
Larry W Tjoelker
Cheryl L Wilder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of ES2159573T3 publication Critical patent/ES2159573T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

EL PRESENTE INVENTO PROPORCIONA SECUENCIAS POLINUCLEOTIDAS PURIFICADAS Y AISLADAS QUE CODIFICAN EL FACTOR ACETILHIDROLASA ACTIVADOR DE PLAQUETAS DEL PLASMA HUMANO. TAMBIEN SE PROPORCIONAN ELEMENTOS Y METODOS PARA LA PRODUCCION RECOMBINANTE DE PRODUCTOS DEL FACTOR ACETILHIDROLASO ACTIVADOR DE PLAQUETAS, LOS CUALES PUEDEN SER UTILES PARA REGULAR LOS CASOS DE INFLAMACON PATOLOGICA.
ES94930623T 1993-10-06 1994-10-06 Acetilhidrolasa del factor activador de plaquetas. Expired - Lifetime ES2159573T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13380393A 1993-10-06 1993-10-06

Publications (1)

Publication Number Publication Date
ES2159573T3 true ES2159573T3 (es) 2001-10-16

Family

ID=22460373

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94930623T Expired - Lifetime ES2159573T3 (es) 1993-10-06 1994-10-06 Acetilhidrolasa del factor activador de plaquetas.
ES00128728T Expired - Lifetime ES2258955T3 (es) 1993-10-06 1994-10-06 Acetilhidrolasa del factor activador de plaquetas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00128728T Expired - Lifetime ES2258955T3 (es) 1993-10-06 1994-10-06 Acetilhidrolasa del factor activador de plaquetas.

Country Status (11)

Country Link
US (5) US5641669A (es)
EP (3) EP0673426B1 (es)
JP (3) JP3613398B2 (es)
AT (2) ATE315655T1 (es)
CA (1) CA2151045C (es)
DE (2) DE69427392T2 (es)
DK (2) DK1096016T3 (es)
ES (2) ES2159573T3 (es)
GR (1) GR3036535T3 (es)
PT (1) PT673426E (es)
WO (1) WO1995009921A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500740A (ja) * 1993-06-25 1996-01-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポタンパク質関連ホスホリパーゼａ▲下２▼、その阻害剤および診断および治療におけるその使用
JP3563091B2 (ja) * 1993-08-03 2004-09-08 第一サントリーファーマ株式会社 酸化リン脂質分解酵素およびその遺伝子
US6146625A (en) * 1993-10-06 2000-11-14 Icos Corporation Platelet-activating factor acetylhydrolase
JP2002515728A (ja) * 1995-09-29 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規用途
JPH11514228A (ja) * 1995-09-29 1999-12-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポ蛋白結合ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）ＰＡＦアセチルヒドロラーゼに対して配列相同性を有する化合物
WO1997021675A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
US6891084B1 (en) * 1996-04-26 2005-05-10 Ajinomoto Co., Inc. DNA encoding raffinose synthase from soybean
AU2698697A (en) * 1996-04-26 1997-11-19 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
US6166292A (en) * 1996-04-26 2000-12-26 Ajinomoto Co., Inc. Raffinose synthetase gene, method of producing raffinose and transgenic plant
JPH1017600A (ja) * 1996-06-28 1998-01-20 Suntory Ltd 血小板活性化因子アセチルヒドロラーゼおよびその遺伝子
IL129262A0 (en) * 1997-08-13 2000-02-17 Icos Corp Truncated platelet-activating factor acetylhydrolase
EP1124970A1 (en) * 1998-10-28 2001-08-22 Smithkline Beecham Plc Process of purification of low density lipoprotein associated phospholipase a2 using immobilized metal affinity chromatography
GB9923790D0 (en) * 1999-10-08 1999-12-08 Isis Innovation Immunoregulatory compositions
PT1686119E (pt) 2000-02-16 2009-10-06 Smithkline Beecham Plc Derivados de pirimidin-4-ona como inibidores de ldl-pla2
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
WO2002097055A2 (en) 2001-05-30 2002-12-05 Ryan James W Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase a2
US7475248B2 (en) 2002-04-29 2009-01-06 International Business Machines Corporation Enhanced message security
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
ATE463562T1 (de) 2003-05-28 2010-04-15 Glaxo Group Ltd Lp-pla2-aktivitätstest mit hohem durchsatz
JP5155564B2 (ja) 2004-02-03 2013-03-06 ディアデクサス インコーポレーテッド Ｌｐ−ＰＬＡ２活性を検出する方法
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
WO2005113797A2 (en) 2004-04-16 2005-12-01 Glaxo Group Limited METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
JP2007145814A (ja) * 2005-10-28 2007-06-14 Bizen Chemical Co Ltd 血小板活性化因子受容体拮抗剤および組成物
CA2649295A1 (en) * 2006-04-21 2007-11-01 Wyeth Methods for high-throughput screening of cell lines
MX2009012188A (es) 2007-05-11 2010-02-24 Univ Jefferson Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos.
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
US8257697B2 (en) * 2007-10-31 2012-09-04 Allertech Laboratory Inc. Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis
JP2009005705A (ja) * 2008-07-02 2009-01-15 Icos Corp 血小板活性化因子アセチルヒドロラーゼ
JP5596964B2 (ja) * 2008-12-02 2014-09-24 協和メデックス株式会社 リポ蛋白中成分の分別定量用標準品の製造方法
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
CN105542010B (zh) * 2015-12-31 2020-11-03 武汉华美生物工程有限公司 脂蛋白相关磷脂酶a2单克隆抗体、抗体对及制备方法、用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
GB9400413D0 (en) 1994-01-11 1994-03-09 Smithkline Beecham Plc Compounds
GB9313144D0 (en) 1993-06-25 1993-08-11 Smithkline Beecham Plc Compounds
JPH08500740A (ja) * 1993-06-25 1996-01-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポタンパク質関連ホスホリパーゼａ▲下２▼、その阻害剤および診断および治療におけるその使用

Also Published As

Publication number Publication date
EP1634953A3 (en) 2006-06-28
JP2006056901A (ja) 2006-03-02
DK0673426T3 (da) 2001-08-27
PT673426E (pt) 2001-11-30
DE69434609T2 (de) 2006-09-21
EP0673426A1 (en) 1995-09-27
HK1012023A1 (en) 1999-07-23
ATE315655T1 (de) 2006-02-15
CA2151045A1 (en) 1995-04-13
EP1096016B1 (en) 2006-01-11
US5641669A (en) 1997-06-24
JP3759941B2 (ja) 2006-03-29
CA2151045C (en) 2002-04-30
DE69427392D1 (de) 2001-07-12
EP1634953A2 (en) 2006-03-15
US5698403A (en) 1997-12-16
US5605801A (en) 1997-02-25
HK1038587A1 (en) 2002-03-22
EP0673426B1 (en) 2001-06-06
DE69427392T2 (de) 2002-05-23
US20050100540A1 (en) 2005-05-12
EP1096016A1 (en) 2001-05-02
DK1096016T3 (da) 2006-05-29
US5532152A (en) 1996-07-02
JP3613398B2 (ja) 2005-01-26
ATE201905T1 (de) 2001-06-15
ES2258955T3 (es) 2006-09-16
JP2004129671A (ja) 2004-04-30
JPH08504603A (ja) 1996-05-21
DE69434609D1 (de) 2006-04-06
WO1995009921A1 (en) 1995-04-13
GR3036535T3 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
ES2159573T3 (es) Acetilhidrolasa del factor activador de plaquetas.
GR3024850T3 (en) Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
AP9100310A0 (en) Tnf inhibitors
IL99769A0 (en) Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69411692D1 (de) Mittel zur Förderung der Proliferationen von Bifidobacterium
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
DE69435270D1 (de) Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
ATE143972T1 (de) 2-substituierte indane-2-carboxyalkyl- verbindungen mit enkephalinase und ace- hemmwirkung
BRPI9711137B8 (pt) composição farmacêutica para reversão de fenótipo canceroso de uma célula cancerosa
DK1029921T3 (da) Serpinresistent t-PA, mutanter, gener
IL196900A0 (en) Autologous t-cell vaccines compositions
DE3888360D1 (de) Hochspannungsschalter und verfahren zur ansteuerung von verbrauchern mittels des hochspannungsschalters.
EP0244361A3 (en) Individual beta-form crystals of tetrakis-û3-(3,5-di-t-butyl-4-hydroxyphenyl)-propionyloxymethyl¨ methane and process for their manufacture
CA2267994A1 (en) Truncated platelet-activating factor acetylhydrolase
IT9021986A0 (it) Procedimento e mezzi per la produzione continua di corpi di carbone
ATA247988A (de) Vormaterial fuer die erzeugung von verbundwerkstoffen
ES2095233T3 (es) Produccion eficaz de proteasa mutante.
ATE10204T1 (de) Saccharose-mutase, immobilisierte saccharosemutase und verwendung von dieser immobilisierten saccharose-mutase zur herstellung von isomaltulose (6-0-alpha-d-glucopyranosido-d- fructose).
BG102061A (en) 4,4-disubstituted cyclohexan-1-ol monomers and compounds based on them
ES2062332T3 (es) Benzoxazolonas antiinflamatorias.
IL101743A0 (en) 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors
PL341071A1 (en) Method of obtaining cleistogamouic mutants of hybridized plants
DE69427794D1 (de) Verbesserungen an Erdmühlen zur Herstellung von Terrakotta-Produkten
ATE315583T1 (de) Analoge des thymosin alpha 1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 673426

Country of ref document: ES